within Pharmacolibrary.Drugs.ATC.J;

model J04AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.82,
    Cl             = 0.00011666666666666667,
    adminDuration  = 600,
    adminMass      = 4000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04AA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>4-aminosalicylic acid (PAS) is an antimycobacterial agent used primarily in the treatment of tuberculosis, especially multidrug-resistant strains. It is typically utilized in combination regimens. While it was a mainstay prior to the advent of more effective drugs, PAS is currently approved and reserved mainly for drug-resistant cases.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Klotz, U, &amp; Maier, KE (1987). Pharmacology and pharmacokinetics of 5-aminosalicylic acid. <i>Digestive diseases and sciences</i> 32(12 Suppl) 46S–50S. DOI:<a href=&quot;https://doi.org/10.1007/BF01312463&quot;>10.1007/BF01312463</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3319458/&quot;>https://pubmed.ncbi.nlm.nih.gov/3319458</a></p></li><li><p>Park, B, et al., &amp; Shim, MK (2024). Mucoadhesive Mesalamine Prodrug Nanoassemblies to Target Intestinal Macrophages for the Treatment of Inflammatory Bowel Disease. <i>ACS nano</i> 18(25) 16297–16311. DOI:<a href=&quot;https://doi.org/10.1021/acsnano.4c05544&quot;>10.1021/acsnano.4c05544</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38867457/&quot;>https://pubmed.ncbi.nlm.nih.gov/38867457</a></p></li><li><p>Klotz, U (1985). Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. <i>Clinical pharmacokinetics</i> 10(4) 285–302. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198510040-00001&quot;>10.2165/00003088-198510040-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2864155/&quot;>https://pubmed.ncbi.nlm.nih.gov/2864155</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04AA01;
